Abstract

Serum sickness, a reaction characterized by fever, rash, myalgia, and arthralgia, can occur in patients who receive chimeric monoclonal antibody therapy. Serum sickness is considered as a rare adverse event following rituximab therapy. We report a case of serum sickness in a newly treated patient with rituximab for pemphigus vulgaris.